Glumin XR 1000mg sustained-release tablets

Ferron Par Pharmaceuticals

Ingredients in every sustained-release tablet

Metformin HCL 1000 mg

Each package contains

4 blisters of 15 sustained-release tablets

Other details

Dosage form:Tablet; coated; sustained-release
Flavour: None

W.H.O. classification

ATC Level 1: A - Alimentary tract and metabolism
ATC Level 2: A10 - Drugs Used in Diabetes
ATC Level 3: A10B - Blood Glucose Lowering Drugs; excl. Insulins



NOT SAFEThis item is not safe for use during pregnancy.


NOT SAFEThis item is not safe for use during lactation.


NOT SAFEThis item should not be used with alcohol.


CAUTIONThis item may not be safe for use while operating heavy machinery. Use with caution.

Available in


Dosage information

Single dose Glumin XR 500,750 and 1000 mg:
– The initial dose of Glumin XR is one caplet 500 mg once a day.
– After 10 to 15 days the dose must be adjusted to the measurement of blood glucose. Enhancement
dosage slowly improves gastrointestinal tolerance. The maximum dose is
recommended is 4 Glumin XR 500 mg caplets a day
– If glycemic control is not achieved with administration of Glumin XR at a dose of 2,000 mg once a day,
administration of Glumin XR 1,000 mg twice daily can be considered, both are given
along with food. If glycemic control is still not achieved, patients can be given tablets
standard metformin up to a maximum dose of 3000 mg a day.
– In patients who have received metformin tablets, the initial dose of Glumin XR should be equivalent
Daily dosage of metformin tablets is released fast. In patients given metformin treatment with
doses above 2000 mg daily, replacement with Glumin XR is not recommended
– If replacement and other oral antidiabetic drugs are to be made: stop using antidiabetic
and start the Glumin XR dose as indicated above.

GLUMIN XR should not be used in children.

Due to the potential for decreased renal function in elderly patients, the metformin dosage should be adjusted based on renal function. Regular assessment of renal function is necessary.


As mono– or combined therapy with sulphonylurea in patients with Non-insulin-dependent diabetes mellitus (type 2 diabetes) especially if overweight and whose blood glucose level cannot be controlled by diet alone.
As an adjuvant therapy in insulin-dependent diabetic patients with hardly controlled symptoms.


The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for informational purposes only. This tool may not cover all possible drug interactions or all warnings or alerts. Please check with a physician if you have health questions or concerns about interactions or go to the appropriate government authority for a comprehensive list of medical warnings. Although we attempt to provide accurate and up-to-date information, no guarantee is made to that effect.

All of the content present on this website, including written text, photographs, videos, graphics, and other resources we might include (these will fall under the collective term of “website”), is meant to educate and should not be perceived as a substitution for professional medical advice, diagnosis or treatment. You should not resort to the website information to arrive at a diagnosis or treatment solution for your health problems or various medical conditions. It does not replace medical care, provided by a medical specialist. In the situation, you have specific symptoms and you might suspect that you are suffering from a medical problem, it is for the best to consult your physician.